Aptevo Therapeutics Files 8-K for Material Agreement
Ticker: APVO · Form: 8-K · Filed: Apr 22, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-filing
Related Tickers: APVO
TL;DR
APVO filed an 8-K for a material agreement – big news coming.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on April 22, 2025, reporting an entry into a material definitive agreement and other events. The filing details their principal executive offices located at 2401 4th Ave, Suite 1050, Seattle, WA 98121, with a phone number of (206) 838-0500. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This 8-K filing indicates a significant development for Aptevo Therapeutics, likely involving a new contract or partnership that could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, making the company's future trajectory uncertain until more details are disclosed.
Key Numbers
- 001-37746 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1567056 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- 2401 4th Ave, Suite 1050, Seattle, WA 98121 (location) — Principal Executive Offices
- 206-838-0500 (phone_number) — Business Phone
- Delaware (jurisdiction) — State of Incorporation
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the nature of the material definitive agreement entered into by Aptevo Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one was entered into as of April 21, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated April 21, 2025.
What is Aptevo Therapeutics' primary business sector?
Aptevo Therapeutics is in the Pharmaceutical Preparations sector, indicated by SIC code 2834.
Where are Aptevo Therapeutics' principal executive offices located?
Their principal executive offices are located at 2401 4th Ave, Suite 1050, Seattle, Washington 98121.
What is the filing date of this 8-K report?
This 8-K report was filed on April 22, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2025 regarding Aptevo Therapeutics Inc. (APVO).